| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022811 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| 01/30/2003 | US20030022366 Method for increasing survival rate of cells in animal cell culture under hypoxia condition |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030022321 Novel compounds |
| 01/30/2003 | US20030022315 Expression of preferential gene in cells; obtain cell, incubate with vector, transform cells, express vector, monitor gene expression inhibition |
| 01/30/2003 | US20030022303 Expression vector for use in the treatment of blood disorders |
| 01/30/2003 | US20030022284 Polypeptide for use in the diagnosis and treatment of kidney defects |
| 01/30/2003 | US20030022283 Neuropeptide Y receptor Y5 and nucleic acid sequences |
| 01/30/2003 | US20030022275 Human nk-3 related prostate specific gene-1 |
| 01/30/2003 | US20030022267 Monitoring the physiological effect of a composition on animal; obtain animal, administer moulator, record physiological adjustments |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030022185 Secreted protein HLHFP03 |
| 01/30/2003 | US20030022181 Streptococcus pneumoniae antigens |
| 01/30/2003 | US20030022178 Identification of sortase gene |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030022149 Enhanced production of safe plasma preparations |
| 01/30/2003 | US20030021859 Therapy for menstraution diseases, anticancer agents, cardiovascular disorders; mixture containing isoflavone |
| 01/30/2003 | US20030021858 Mixture of jasmone compound, antioxidant and carnitine |
| 01/30/2003 | US20030021857 Plant extracts; viricides, blood flow, alopecia |
| 01/30/2003 | US20030021856 New use of ammonium compounds and/or urea |
| 01/30/2003 | US20030021855 Topical applying |
| 01/30/2003 | US20030021850 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ |
| 01/30/2003 | US20030021846 Sustained release; wet granulation, compaction |
| 01/30/2003 | US20030021845 Gastroretentive controlled release pharmaceutical dosage forms |
| 01/30/2003 | US20030021843 Antidiabetic preparation for oral administration |
| 01/30/2003 | US20030021841 Metformin hydrochloride; blending, compression |
| 01/30/2003 | US20030021840 High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same |
| 01/30/2003 | US20030021838 Anticancer agents; vaccines; induction immunology response |
| 01/30/2003 | US20030021836 Magnesium di-potassium EDTA complex and method of administration |
| 01/30/2003 | US20030021834 Method for use of hyaluronic acid in wound management |
| 01/30/2003 | US20030021833 Administering selegiline, or metabolite thereof |
| 01/30/2003 | US20030021829 Removal eye dryness; adsorption polyvinylpyrrolidone |
| 01/30/2003 | US20030021828 Method for treating and/or preventing retinal diseases with substained release corticosteroids |
| 01/30/2003 | US20030021818 Spraying microbiocide |
| 01/30/2003 | US20030021816 Antiinflammation agents, antiscarring agent; administering immunosuppressant |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021788 Novel human STRA6-like protein and nucleic acids encoding the same |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021786 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021781 Administering antibodies |
| 01/30/2003 | US20030021779 Immunology response; monoclonal antibodies |
| 01/30/2003 | US20030021777 Product comprising bound fibrinogen and thrombin for use in wound therapy or surgical repair |
| 01/30/2003 | US20030021772 Method for treating effects of sleep deprivation and jet lag with NADPH and NADPH |
| 01/30/2003 | US20030021768 Viral mutants that selectively replicate in targeted human cancer cells |
| 01/30/2003 | US20030021761 Ionene polymers and their use in treating mucositis |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2733813A1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2 |
| 01/30/2003 | CA2682251A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | CA2470958A1 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 01/30/2003 | CA2457308A1 Controlled drug delivery systems providing variable release rates |
| 01/30/2003 | CA2454545A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity |
| 01/30/2003 | CA2454543A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]naphthalenyl derivatives with antipsychotic activity |
| 01/30/2003 | CA2454357A1 An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration |
| 01/30/2003 | CA2454200A1 Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| 01/30/2003 | CA2454187A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | CA2454171A1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 01/30/2003 | CA2454167A1 Use of a class of antiviral compounds to produce an agent for treating or preventing a virus infection in the respiratory tract |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2454049A1 Carbamate compounds for use in preventing or treating neuropathic pain |
| 01/30/2003 | CA2454043A1 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement |
| 01/30/2003 | CA2454007A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | CA2454002A1 Regulator for amount of body fat |
| 01/30/2003 | CA2453997A1 Porphyrin derivatives for photodynamic therapy |
| 01/30/2003 | CA2453993A1 Method and composition for treatment of cancer |
| 01/30/2003 | CA2453986A1 Glycoprotein vi fusion proteins |
| 01/30/2003 | CA2453860A1 Imidazopyridinones as p38 map kinase inhibitors |
| 01/30/2003 | CA2453846A1 Substituted isoxazoles and the use thereof as antibiotics |
| 01/30/2003 | CA2453834A1 Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions |
| 01/30/2003 | CA2453765A1 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | CA2453650A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453633A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | CA2453631A1 Process and intermediates to prepare latanoprost |
| 01/30/2003 | CA2453616A1 Pharmaceutical preparations containing ion exchange resins charged with active ingredients |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453594A1 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 01/30/2003 | CA2453478A1 Agent for treatment of cerebral ischemic diseases |
| 01/30/2003 | CA2453473A1 Water-free ubichinon concentrate |
| 01/30/2003 | CA2453342A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | CA2453296A1 Solvent-free anthracycline derivatives |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2453290A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 01/30/2003 | CA2453249A1 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | CA2453108A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452653A1 Silencing of gene expression by sirna |
| 01/30/2003 | CA2452541A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | CA2452518A1 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | CA2452357A1 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2452009A1 Chemical compounds |
| 01/30/2003 | CA2451881A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2451445A1 Imidazo-triazine derivatives as ligands for gaba receptors |